拉皮托伊尔卡尼丁 (L-Palmitoylcarnitine) 增强了等离子素和tPA的作用,以抑制血栓形成

相关实验视频

Updated: Jul 11, 2025

10:37

Ferric Chloride-induced Murine Thrombosis Models

Published on: September 5, 2016

21.7K

Juan Yang¹, Lina Cha², Yepeng Wang³

¹Department of Anesthesiology, First Affiliated Hospital of Kunming Medical University, Kunming, 650032, China.

Natural products and bioprospecting

|November 8, 2023

概括

脂肪酸代谢物L-帕尔米托伊尔卡尼丁 (L-PC) 显示出显著的抗血栓作用. 它增强了等离子体和组织等离子体激活剂 (tPA) 的活性,抑制了血栓形成,出血风险最小.

科学领域:

生物化学生物化学
药理学药理学是指药理学的学科.
心血管研究研究心血管研究

背景情况:

L-棕甲基尼丁 (L-PC) 是一种内源性脂肪酸代谢产物.
经典功能包括膜动力学和脂肪酸β-氧化.
长链乙基卡尼丁的减少与血栓形成有关,这表明抗凝剂的作用.

研究的目的:

研究L-棕甲基卡尼丁 (L-PC) 在凝血中的作用.
为了确定L-PC是否具有抗血栓性质.
阐明L-PC潜在的抗凝固作用背后的机制.

主要方法:

在体外测定测量等离子体和组织等离子体激活剂 (tPA) 在存在L-PC.的酶活性.
直接结合研究,以确定L-PC和等离子体/tPA之间的平衡解离常数 (KD).
在体内小鼠模型:FeCl3诱导的动脉血栓和短暂的中脑动脉封闭 (tMCAO) 模型.

主要成果:

L-PC显著增强了等离子体和tPA的酶活性.
L-PC与等离子体 (KD = 6.47 × 10−9 M) 和tPA (KD = 4.46 × 10−9 M) 呈现出高亲和度的直接相互作用.
在体内,L-PC的使用抑制了动脉血栓形成,缓解了脑血栓和炎症,并引起了极小的出血并发症.

结论:

L-棕甲基卡尼丁 (L-PC) 具有显著的抗血栓功能.
L-PC通过增强等离子体和tPA的活性来发挥其抗血栓作用.
对于血栓性疾病来说,L-PC是一种潜在的治疗药物,在出血方面具有有利的安全性.

关键词:

凝血是凝固的过程.这是一种L-palmitoylcarnitine.塑胺是一种可塑性物质.血栓形成的原因之一是血栓形成.组织类型的塑原激活剂激活剂

相关概念视频

01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

535

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...

535

01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

719

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...

719

01:16

Clot Retraction and Fibrinolysis

6.2K

After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.

6.2K

01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

190

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...

190

01:27

Peripheral Artery Disease III: Interprofessional Care

Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...

01:29

Venous Thrombosis III: Interprofessional Care

Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...